GSK3882347 for Urinary Tract Infection (UTI)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new medication, GSK3882347, to treat urinary tract infections in adult women. The study will see if the medication can effectively clear the infection and check for any side effects. Participants will take the medication for a short period, and researchers will compare it to an existing treatment to ensure accurate results.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have taken other systemic antimicrobials or systemic antifungals within 1 week (or 10 weeks for dalbavancin or oritavancin) before joining the study.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have taken other systemic antimicrobials or systemic antifungals within 1 week before the study, or 10 weeks for certain drugs like dalbavancin or oritavancin.
What safety data exists for GSK3882347 (Nitrofurantoin) in treating urinary tract infections?
Nitrofurantoin, also known as GSK3882347, has been used successfully for a long time to treat urinary tract infections and is generally considered safe. Studies have shown it to be effective in adults, children, and pregnant women, with no significant adverse effects on fetal development. However, rare adverse reactions, such as systemic inflammatory response syndrome, have been reported. Overall, nitrofurantoin is well-tolerated, but patients should be informed about potential side effects.12345
What safety data exists for GSK3882347 (Nitrofurantoin) in humans?
Nitrofurantoin has been used safely for a long time to treat urinary tract infections in adults, children, and pregnant women, with no significant safety concerns reported. However, there are rare cases of serious side effects, such as a systemic inflammatory response, which should be monitored.12345
Is the drug Nitrofurantoin a promising treatment for urinary tract infections?
Yes, Nitrofurantoin is a promising treatment for urinary tract infections. It has been used successfully for many years and remains effective against common bacteria that cause these infections. It is especially useful now because it works well against bacteria that are resistant to other antibiotics.14678
How is the drug GSK3882347 different from other treatments for urinary tract infections?
What data supports the idea that GSK3882347 for Urinary Tract Infection is an effective drug?
The available research shows that nitrofurantoin, which is another name for GSK3882347, has been used successfully for many years to treat urinary tract infections. It remains effective against common bacteria that cause these infections, like Escherichia coli. Recent studies suggest that short-term use of nitrofurantoin is as effective as other standard treatments, and it is recommended as a first-choice treatment for uncomplicated urinary tract infections in healthy women. However, it should be used cautiously in people with kidney problems and during the last three months of pregnancy.12689
What data supports the effectiveness of the drug GSK3882347 for urinary tract infections?
Nitrofurantoin, a component of the treatment, has been used successfully for many years to treat urinary tract infections, especially in cases where bacteria are resistant to other antibiotics. It is effective against common bacteria that cause these infections, making it a reliable option for treatment.12689
Who Is on the Research Team?
GSK Clinical Trials
Principal Investigator
GlaxoSmithKline
Are You a Good Fit for This Trial?
This trial is for adult women aged 18-70 with uncomplicated urinary tract infections (uUTI), not pregnant or breastfeeding, and using effective contraception. They must have symptoms like pain during urination, frequent urge to urinate, or lower abdominal pain. Women with immune issues, other diseases causing similar symptoms, urinary anomalies, severe kidney problems, recent antimicrobial treatment or high alcohol intake are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily oral dosing of GSK3882347 or nitrofurantoin for 5 days
Test of Cure (ToC)
Microbiological response is evaluated at the test of cure visit
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- GSK3882347
- Nitrofurantoin
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School